AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03308487 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (2000 IU)
Study NCT03114722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citrate 4%
Description: In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
Study NCT03114722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparinised saline (10U/ml)
Description: In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
Study NCT00735124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 1200 mg single dose gabapentin
Study NCT00735124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injection of placebo/sham
Study NCT04289129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric evaluation
Description: Vertically placed on the muscle, a probe (3 mm diameter) creates constant pre-excitations (0.18 N) and generates short-term (15 ms), low-force (0.4 N) mechanical stimulations.
Study NCT03102944 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Minicare BNP
Description: no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
Study NCT00719576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous cultured chondrocytes on porcine collagen membrane
Description: Implantation via mini-arthrotomy
Study NCT00719576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture performed by arthroscopic surgery
Study NCT00678275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ATG FRESENIUS (Anti-Lymphocyte-Globulin)
Description: conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
Study NCT00678275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ATG FRESENIUS (Anti-Lymphocyte-Globulin)
Description: conditioning regimen WITHOUT ATG when randomised Arm B
Study NCT01218932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A
Description: Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
Study NCT01218932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
Study NCT02592603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endocuff-assisted Colonoscopy
Description: Colonic examination with Endocuff-assisted Colonoscopy
Study NCT03554005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG Interferon Alfa-2b
Description: Participants receive PEG interferon alfa-2b administered by SC injection, in doses ranging from 0.75 mcg/kg OW up to 7.5 mcg/kg OW, for up to 40 weeks of treatment.
Study NCT02899403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Visual Information Processing (RVIP) test
Description: Rapid Visual Information Processing is a measure of sustained attention.
Study NCT02423694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electro-acupuncture
Description: 8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.~Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5\~1.0 mA
Study NCT02423694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram oxalate tablets
Description: escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
Study NCT04605666 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-CAR-T2 Cells
Description: CD19-CAR-T2 T cells will be infused over 10-15 minutes on Day 0.
Study NCT03554005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Participants receive 500 to 1000 mg of acetaminophen orally 30 minutes prior to PEG interferon alfa-2b administration, and continue acetaminophen 500 to 1000 mg after administration every 4 to 6 hours as needed. The total daily dose of acetaminophen should not exceed 3000 mg.
Study NCT04913714 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 3-month radio intervention on infant vaccination
Description: Radio intervention comprising 10-minute drama, 10-minute discussion of the drama by trained health extension workers and 30-minute phone-in from listeners
Study NCT01227538 — intervention group
Intervention type: OTHER
Intervention: Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function
Description: Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
Study NCT01201070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antithrombin III
Description: 3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
Study NCT02834052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
Study NCT02834052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:~Week 1, Days 1 and 4~Week 2, Days 8 and 11~Week 3, Days 15 and 18
Study NCT02194400 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSLV-132
Description: 0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
Study NCT02194400 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSLV-132
Description: 0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
Study NCT01968096 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: home-based ankle continuous passive motion machine.
Description: A rehabilitation program of machine driven passive stretch.
Study NCT03696758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Testing
Description: Subjects will undergo spirometry, Plethysmography, and diffusion capacity.
Study NCT03696758 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Subjects will undergo an electrocardiogram to ensure sinus rhythm
Study NCT04064905 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1893
Description: Zika vaccine
Study NCT04064905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02921256 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity modulated radiation therapy
Study NCT02921256 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity modulated radiation therapy
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT03592329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tVNS
Description: non-painful electrical stimulation of the auricle
Study NCT03592329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction Training B
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions
Study NCT03592329 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stress Reduction Training B
Description: twice weekly booster sessions and weekly instructor-led sessions for 8 weeks plus home practice sessions
Study NCT03592329 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: sham tVNS
Description: sham stimulation
Study NCT03527654 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Surveys, blood and urine collected prospectively over 24 months.
Study NCT01010035 — intervention group
Intervention type: OTHER
Intervention: Plasma kinetic study
Description: this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
Study NCT02593344 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endopat
Description: measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
Study NCT02371993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Study NCT02371993 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Choline
Study NCT02371993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02371993 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03485482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: bisoprolo 5 mg tablets
Study NCT03485482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 10 mg tablet
Study NCT03485482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of Ivabradine and bisoprolol
Description: combination of 10 mg ivabradine and 5 mg bisoprolol
Study NCT02409940 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal Stem Cells
Description: These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
Study NCT02409940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
Study NCT01675076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: NOAC
Study NCT01675076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: NOAC
Study NCT01675076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: NOAC
Study NCT01675076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: NOAC
Study NCT01675076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: NOAC
Study NCT01675076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: NOAC
Study NCT01281787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
Study NCT01281787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
Study NCT01098110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg
Description: Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
Study NCT01098110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine 10 mg
Description: Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
Study NCT01098110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo of asenapine sublingual tablet not containing asenapine
Study NCT02344745 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavandula angustifolia essential oil (Aura Cacia)
Description: The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
Study NCT02344745 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
Study NCT04596124 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fitostimoline plus
Description: randomized controlled multicentric study
Study NCT04596124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fitostimoline plus
Description: randomized controlled multicentric study
Study NCT04667936 — intervention group
Intervention type: OTHER
Intervention: Treatment group
Description: None, solely treatment documentation
Study NCT02078921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate
Study NCT02078921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06207292 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions
Study NCT04467099 — intervention group
Intervention type: OTHER
Intervention: Foot Exam Follow-Up
Description: All participants will have a clinical assessment of their surgery foot by the study doctor.
Study NCT04467099 — intervention group
Intervention type: RADIATION
Intervention: X-ray
Description: Standard x-ray of the foot.
Study NCT04467099 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: All participants will complete a questionnaire.
Study NCT03490916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Administration of Acetazolamide
Study NCT03490916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of Placebo
Study NCT02010255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF FDC tablet administered orally once daily
Study NCT00639431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: direct observation
Description: direct observation of another person's foot moving
Study NCT00639431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental visualization
Description: mentally imagining moving one's phantom foot/feet
Study NCT00972582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine Increase
Description: Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
Study NCT04676178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRA023
Description: PRA023
Study NCT04676178 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02911857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Canakinumab (AIN457)
Description: Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution
Study NCT00545766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
Study NCT02021032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prolieve
Description: Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
Study NCT02004483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
Study NCT02114801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: manual brushing
Description: Tooth brushing
Study NCT02114801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electric toothbrush linked
Description: Tooth brushing
Study NCT02114801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: off electric toothbrush
Description: Tooth brushing
Study NCT03665454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562
Description: PF-06412562 is a dopamine agonist developed by Pfizer Inc. into a tablet form for oral usage. It will be provided as 5 mg tablets. Thus, to administer the 25 mg dose, 5 x 5 mg tablets will be given; and to administer the 20 mg dose, 4 x 5 mg tablets will be administered.
Study NCT03665454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Placebo
Description: 25/100 mg tablet(s) of carbidopa/levodopa will be encapsulated and administered according to the subject's home regimen.
Study NCT01524757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: pantoprazole 40mg 1dd1; 12 months
Study NCT01524757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pantoprazole
Description: pantoprazole 40mg 1dd1; 12 months
Study NCT03375008 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Imaging diagnostic and biopsy
Description: Liver biopsy and MRI scan
Study NCT01557049 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: No physical intervention was given, patients were treated only with medication if necessary.
Study NCT02921256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00013143 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient risk profiling (potential ADEs) w/provider feedback
Study NCT02921256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT00103844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks